13F HOLDINGS REPORT
Decheng Capital LLC
Quarter ended Q4 2025 · Filed February 12, 2026 · Accession 0001104659-26-014146
Total Value
$743.4M
Positions
19
Other Managers
0
Confidential Omitted
No
Holdings (19)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 6,371,669 | $264.6M | 35.59% |
| 2 | Nuvation Bio Inc. | NUVB | 25,954,439 | $232.6M | 31.28% |
| 3 | Upstream Bio Inc. | UPB | 3,143,078 | $85.3M | 11.48% |
| 4 | AARDVARK THERAPEUTICS INC | AARD | 3,917,299 | $51.4M | 6.92% |
| 5 | Lyell Immunopharma, Inc. | LYEL | 692,050 | $21.3M | 2.87% |
| 6 | NEWAMSTERDAM PHARMA CO NV | NAMSW | 592,057 | $20.8M | 2.79% |
| 7 | REVOLUTION MEDICINES INC(NSM) | RVMDW | 200,000 | $15.9M | 2.14% |
| 8 | Arcus Biosciences, Inc | RCUS | 541,559 | $12.9M | 1.74% |
| 9 | Aclaris Therapeutics, Inc. | ACRS | 4,041,736 | $12.2M | 1.64% |
| 10 | Equillium Inc. | EQ | 4,447,308 | $6.9M | 0.93% |
| 11 | BeyondSpring Inc. | BYSI | 3,800,702 | $6.2M | 0.83% |
| 12 | CRINETICS PHARMACEUTICALS IN | CRNX | 92,700 | $4.3M | 0.58% |
| 13 | KRYSTAL BIOTECH INC | KRYS | 17,300 | $4.3M | 0.57% |
| 14 | Aura Biosciences, Inc. | AURA | 360,483 | $2.0M | 0.26% |
| 15 | Zentalis Pharmaceuticals Inc. | ZNTL | 1,323,327 | $1.8M | 0.24% |
| 16 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 326,810 | $375,832 | 0.05% |
| 17 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 44,311 | $332,333 | 0.04% |
| 18 | Nuvation Bio Inc. | NUVB | 646,057 | $213,198 | 0.03% |
| 19 | REZOLUTE INC | RZLT | 59,900 | $141,364 | 0.02% |